Defense Health Agency to Utilize AI, Data Analytics to Enhance PTSD Treatment
The agency has partnered with AiCure to deploy artificial intelligence solutions as part of its PTSD Drug Treatment Program, which aims to optimize treatment and increase patient support.
- The US Defense Health Agency (DHA) has announced that its PTSD Drug Treatment (PTSD-DT) Program will utilize New York-based artificial intelligence (AI) and data analytics company AiCure’s medication adherence and digital biomarker solutions to evaluate the efficacy of multiple PTSD treatments in service members and veterans.
Estimates of PTSD prevalence vary, but the US Department of Veterans Affairs’ National Center for PTSD reports that the National Comorbidity Survey Replication (NCS-R), conducted between February 2001 and April 2003, found that the lifetime prevalence of PTSD among adult Americans was 6.8 percent. Lifetime prevalence of PTSD was estimated to be 3.6 percent among men and 9.7 among women.
PTSD prevalence is higher in veterans than in the general population, with some variance depending on the veteran cohort. For example, the estimated lifetime prevalence of PTSD among Gulf War veterans is between 10.1 and 12.1 percent, compared to an estimated lifetime prevalence of 13.8 percent for those deployed during Operation Enduring Freedom and Operation Iraqi Freedom in Afghanistan and Iraq, according to the report.